anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background: Women with gestational diabetes mellitus (GDM) are more likely to develop cardiometabolic risk (CMR). CMR refers to the risk factors that promote the chance of developing type 2 diabetes mellitus or cardiovascular events. However, using a family-centered approach, the effectiveness of continuous administration of both mobile health management and theoretical based lifestyle intervention from pregnancy to postpartum in preventing women at high risk of GDM from developing CMR has rarely been studied.

Methods: This randomized controlled trial will recruit 120 GDM pregnant women in northern Taiwan. The participants will be randomly assigned to the control group (blood glucose meters (BGM); n=40 people), intervention group 1 (continuous glucose monitoring (CGM); n=40 people), intervention group 2 (HBM-based lifestyle and mHealth intervention + CGM; n=40 people).The comparison group will receive the routine care and finger-prick test for blood glucose monitoring (BGM) during pregnancy.The intervention group 1 will receive CGM during pregnancy. The intervention group 2 will receive a HBM-based lifestyle and mHealth management program on 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum, including CGM during pregnancy.We intend to compare outcome variables among three groups. The outcomes variables will be assessed at baseline (24-32 weeks of pregnancy), 33 weeks of pregnancy to before delivery, 4 to 12 weeks after delivery. The primary outcomes were maternal glycemic parameters, cardiometabolic risk factors, and maternal health behavior. Outcomes will be assessed at baseline (24-32 weeks of pregnancy), 33 weeks of pregnancy to before delivery, 4 to 12 weeks after delivery. Generalized estimating equation (GEE) will be used to examine the trajectories and the effectiveness of the project for managing cardiometabolic risk on cardiometabolic risk and health behavior.
An inorganic complex powder which is coated with a silica solid lipid layer is provided to continuously contain drug and improve the function of controlled release. A complex contains plate shape inorganic material and silica solid lipid layer. The silica solid lipid layer is coated on the inorganic material. The silica solid lipid layer is formed through silicification of hydrophilic head domain in phospholipid. The inorganic material is talc or sericite. A method for manufacturing the complex comprises: a step (a) of chelating the organic material with bivalent metal; a step (b) of coating lipid component on the chelated inorganic material; and a step (c) of forming the silicate coating on the lipid-coated organic material. A drug delivery system contains the drug using the complex.
The present invention relates to a method for preparing lipophilic drug-containing solid lipid nanoparticles surface-modified with an N-trimethyl chitosan graft palmitic acid polymer. The method according to the present invention comprises the steps of: providing an N-trimethyl chitosan graft palmitic acid polymer and lipophilic drug-containing solid lipid nanoparticles separately; and mixing the polymer with the nanoparticles. The present invention also relates to the lipophilic drug-containing solid lipid nanoparticles surface-modified with the N-trimethyl chitosan graft palmitic acid polymer obtained by the method, and a resveratrol formulation for oral administration comprising the nanoparticles and resveratrol encapsulated therein. The solid lipid nanoparticles having a lipophilic drug encapsulated therein and surface-modified with the N-trimethyl chitosan graft palmitic acid polymer are stable even under an acidic gastrointestinal environmental by virtue of the coating with the polymer and thus allow continuous release of the lipophilic drug in the intestines. Thus, it is possible to improve the absorption ratio of a lipophilic drug. Therefore, the nanoparticles are useful for a formulation for oral administration of the lipophilic drug.
Control participants will care for the same set of CPV patients as the intervention arm, but will not have knowledge of or access to GlycoMark 1,5-AG test results. Investigators will compare control participants' clinical recommendations to those in the intervention arm.
Hydrogen supplement has been shown to have significant removing effects on free radicals. International clinical trials have shown promise that hydrogen molecules may reduce chronic inflammatory and then speed up recovering the course of the disease.The purpose of this study is to determine the possible efficacy and safety of hydrogen supplements in different formula and dose exposures for a clinical study in patients with chronic diseases.Study design: 60 chronic diseases patients will be recruited from the Taoyuan Armed Forces General Hospital and Tri-Service General Hospital for this study. Participants will be screened by doctors for their eligibility and undergo a series of tests (questionnaires and examinations).Consenting participants will then be randomly allocated into 2 groups (experiment group and control group, single-blind study). In experiment group, participants will receive 2 solid hydrogen capsules every day for 24 weeks. In control group, participants will receive 2 capsules not containing hydrogen every day for 24 weeks. Participants will be examined their regular haematology, urine and health status before and after the intervention.
The investigators propose recruiting 300 HIV/HCV co-infected PWID (i.e. Index participants). Half will be randomly assigned to the experimental condition and half to the equal attention comparison. The experimental intervention will include 8 group sessions that focus on communication to social network members, medical adherence and risk reduction skills, 2 dyad sessions with network members, monthly booster sessions for 6 months, and mHealth cuing of behavior for 6 months. These Index participants will be followed for 24 months (3, 6, 12, 18, \& 24 month assessments). Participants who test positive for HCV will be linked to the Johns Hopkins Viral Hepatitis clinic to assess liver function and HCV chronicity and if applicable offered HCV treatment. Additionally, 450 network members will be recruited and will be tested for HIV and HCV and followed longitudinally to examine the social diffusion and social network factors associated with adherence among the Index participants.
Adverse events were assessed in BI Trial 1100.1032 (ACTG 245), a double-blind, placebo-controlled trial of Nevirapine (n=305) in which pediatric subjects received combination treatment with Nevirapine. In this trial two subjects were reported to experience Stevens-Johnson syndrome or Stevens-Johnson/toxic epidermal necrolysis transition syndrome. Safety was also assessed in trial BI 1100.882 (ACTG 180), an open-label trial of Nevirapine (n=37) in which subjects were followed for a mean duration of 33.9 months (range: 6.8 months to 5.3 years, including long-term follow-up in 29 of these subjects in trial BI 1100.892). The most frequently reported adverse events related to Nevirapine in pediatric subjects were similar to those observed in adults, with the exception of granulocytopenia, which was more commonly observed in children receiving both zidovudine and Nevirapine. Cases of allergic reaction, including one case of anaphylaxis, were also reported. 

The safety of Nevirapine was also examined in BI Trial 1100.1368, an open-label, randomized clinical trial performed in South Africa in which 123 HIV-1 infected treatment-naïve subjects between 3 months and 16 years of age received combination treatment with Nevirapine oral suspension, lamuvidine and zidovudine for 48 weeks [see Use In Specific Populations (8.4) and Clinical Pharmacology (12.3)]. Rash (all causality) was reported in 21% of the subjects, 4 (3%) of whom discontinued drug due to rash. All 4 subjects experienced the rash early in the course of therapy (less than 4 weeks) and resolved upon nevirapine discontinuation. Other clinically important adverse events (all causality) include neutropenia (9%), anemia (7%) and hepatotoxicity (2%) [see Use in Specific Populations (8.4) and Clinical Studies (14.2)]. 

Safety information on use of Nevirapine in combination therapy in pediatric subjects 2 weeks to less than 3 months of age was assessed in 36 subjects from the BI 1100.1222 (PACTG 356) trial. No unexpected safety findings were observed although granulocytopenia was reported more frequently in this age group compared to the older pediatric age groups and adults.
<P>PROBLEM TO BE SOLVED: To provide a gel sheet which can sufficiently exhibit efficacy of a plant extract.  <P>SOLUTION: This gel sheet 10 is characterized by mixing a gel material for packs with ≥30% of a plant extract and then forming the composition in a sheet shape. The gel is formed from a polyacrylate as a base material or from agar and polyacrylic acid or a polyacrylate as base materials. The gel preferably contains the extracts of one or more plants selected from aloe, carrot, cucumber, peach leave, jojoba, and raspberry. The gel may furthermore contain the extracts of one or more herbs selected from lavender, rosemary, peppermint, Japanese cypress, chamomilla, rose, and chamomile.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Bipolar disorder (BD) is a serious, complex, family-grafting mental illness. Studies have shown that genetic factors may be the dominant factor in the pathogenesis of bipolar disorder, thus, it is worth looking forward to getting started and clarifying the etiology of bipolar disorder from a genetic perspective. However, earlier genetic studies such as linkage analysis, genetic mutation detection (preferred candidate genes), and recent genetic studies (no need to presuppose candidate genes) such as Whole Genome Sequencing (WGS), whole genome GWAS and Whole-exome sequencing (WES) failed to identify any biogenic disorder gene or chromosomal region that plays a major role in, which may be related to the synergy of population heterogeneity, insufficient sample size or coordination effect caused by common mutations.

As a familial, highly heritable psychiatric disease, the literature suggests that the pathogenic genes of bipolar disorder may be directly derived from the intergenerational transmission of rare mutations in family members, and these rare variants are more likely to be predicated from the family. It has been found that the family has a higher frequency and is more susceptible to detecting susceptibility genes for bipolar disorder. Therefore, the family research design combined with WGS, GWAS and other advanced genetic research methods can reduce the unnecessary sample size, eliminate the confounding factors of the population, and more easily capture the potential genes of bipolar disorder.

However, at present, there are few reports of foreign bipolar disorder family and the results are not consistent. There is no research report on the large sample family of Chinese Han population in China. Therefore, it is necessary to expand the family sample size and combine with new genetic research methods in the Han population. explore. Therefore, this study intends to find out the pathogenic genes of bipolar disorder by collecting the two-phase family of Chinese Han population with the large sample using a family cohort study design, combined with the new generation of high-throughput sequencing technology and GWAS, Proteomics, bioinformatics analysis, etc., which is expected to be clarified at the genetic level. The pathogenesis of bipolar disorder. At the same time, the investigators will conduct a five-year follow-up of cognitive function, brain function imaging and other major clinical symptoms in patients with bipolar disorder in the core family, and to explore familial bipolar disorder and sporadic biphasic. Differences in the clinical features of the disorder, in order to explore sensitive and specific biomarkers from a multidimensional perspective (cognitive function, brain imaging, genetic features, clinical features, etc.), which may contribute to bipolar disorder in the future. Accurate diagnosis and early identification and prevention have important scientific significance and clinical diagnosis and treatment significance.
1. PET/MRI Scan: Image acquisition was completed 15 days before surgery. CXCR4 contrast agent was injected at 6.5 MBq/kg based on body mass, with no drug extravasation, and imaging was performed after 60 minutes of quiet rest. All subjects were scanned in a supine position on a single bed of the Signa™ 3.0T scanner (GE Healthcare Systems), using a 3.0T gem HNU head coil with a scanning field of view focused on the head. PET acquisition lasted for 20 minutes and was reconstructed using OSEM. Simultaneous MRI acquisition included MR-based attenuation correction (MRAC) - zero echo time pulse sequence (ZTE), as well as structural and functional MRI sequences (T1WI, T2WI, FLAIR, DWI, MRS, DSC, T1-CE). Image fusion was performed on a GE post-processing workstation.
2. Image Analysis and Observation Indicators: PET/MRI images were independently reviewed and processed by two experienced neuroradiologists. Using IKT-SNAP software, target lesion VOIs were outlined based on FLAIR and T1-CE sequences. VOI delineation on the FLAIR sequence included solid tumor components, necrotic areas, and surrounding abnormal FLAIR signal regions. VOI delineation on the T1-CE sequence included enhanced solid components, non-enhanced solid components, and necrotic areas. MRI parameters (diffusion-weighted imaging parameters: ADC; perfusion imaging parameters: CBF, CBV, MTT, TTP; spectroscopic parameters: NAA, Cho, Cr, Lac, NAA/Cr, Cho/Cr) and PET parameters (SUVmax, SUVmean, SUVpeak, CXCR4 metabolic volume, TBR) were measured throughout the tumor and corresponding regions.
3. Pathological Analysis: Slices containing no less than 25% tumor tissue were used, with each slice having a thickness of 4um. HE, CD34, and CXCR4 immunohistochemical staining were performed separately. Two senior pathologists reviewed the slides using a double-blind method. IDH mutation status and 1p/19q deletion status were determined by the pathology department.
Podocyte damage is the major cause of glomerular injury and proteinuria in multiple chronic kidney diseases. Metadherin (MTDH) is involved in podocyte apoptosis and promotes renal tubular injury in mouse models of diabetic nephropathy and renal fibrosis; however, its role in podocyte injury and proteinuria needs further exploration. Here, we show that MTDH was induced in the glomerular podocytes of patients with proteinuric chronic kidney disease and correlated with proteinuria. Podocyte-specific knockout of MTDH in mice reversed proteinuria, attenuated podocyte injury, and prevented glomerulosclerosis after advanced oxidation protein products challenge or adriamycin injury. Furthermore, specific knockout of MTDH in podocytes repressed β-catenin phosphorylation at the Ser675 site and inhibited its downstream target gene transcription. Mechanistically, on the one hand, MTDH increased cAMP and then activated protein kinase A (PKA) to induce β-catenin phosphorylation at the Ser675 site, facilitating the nuclear translocation of MTDH and β-catenin; on the other hand, MTDH induced the deaggregation of pyruvate kinase M2 (PKM2) tetramers and promoted PKM2 monomers to enter the nucleus. This cascade of events leads to the formation of the MTDH/PKM2/β-catenin/CBP/TCF4 transcription complex, thus triggering TCF4-dependent gene transcription. Inhibition of PKA activity by H-89 or blockade of PKM2 deaggregation by TEPP-46 abolished this cascade of events and disrupted transcription complex formation. These results suggest that MTDH induces podocyte injury and proteinuria by assembling the β-catenin-mediated transcription complex by regulating PKA and PKM2 function.
The use of silver due to its antibacterial properties has been used to preserve and treat diseases in agriculture, so that silver nanoparticles can contain silver powders, silver composites, silver compounds and silver salts. The present technology is prepared as follows: Dissolve silver nitrate crystal in distilled water. add surfactant, LABS (linear alkyl benzene sulfonate) to the solution and (3) add reducing agent to the solution. Also, this silver Nano-colloid is prepared at room temperature and its reaction time is 1 hour and it can be synthesized in a shorter time. Silver Nano-colloid of pests, weeds, insects, molds, bacteria and other harmful factors Targets and eliminates the negative impact on health and growth of agricultural products. Another method is to use a Nano-active substance by covering the seed with the active substance and this active substance prevents pathogens from attacking the seeds and improves the growth of the mentioned seeds.
The invention discloses a traditional Chinese medicine for acupoint application to treat child anorexia. The traditional Chinese medicine comprises the following components in parts by weight: 3 parts of roasted white atractylodes rhizome, 2 parts of fructus amomi, 2 parts of amomum cardamomum, 1 part of scorched hawthorn fruit, 1 part of roasted malt and 1 part of raw gizzard lining. The principle that 'Spleen tonifying lies in movement rather than supplement' is taken as a guiding principle in treatment of the disease. The traditional Chinese medicine can be used for strengthening the spleen and harmonizing the stomach as main functions and cannot tonify too much or simply cure indigestion. The roasted roasted white atractylodes rhizome has the effects of tonifying qi and tonifying the spleen as a monarch drug; the fructus amomi and the amomum cardamomum are sweet, have the effects of refreshing the mind, warming the middle warmer and promoting circulation of qi as ministerial drugs, and help the roasted white atractylodes rhizome tonify the spleen, so that the spleen can be transformed; the scorched hawthorn fruit, the roasted malt and the raw gizzard lining have the effects of helping digestion and invigorating the stomach as adjuvant drugs, and can help the roasted white atractylodes rhizome transform water and grain. The overall formula has the effects of tonifying the spleen, warming the middle warmer and promoting circulation of qi, helping digestion and invigorating the stomach in common. Thus, the traditional Chinese medicine has the effects of strengthening the temperament, enhancing the appetite and enhancing the orexia, is flavorous in taste, and is the source of qi and blood.
BACKGROUND: Thoracic esophageal cancer surgery using robotic approaches for the thoracic and abdominal parts has recently been reported as total robot-assisted minimally invasive esophagectomy (RAMIE). We herein present the first report of a new technique for esophageal cancer: total RAMIE with three-field lymph node dissection (3FLND) by a simultaneous two-team approach using a new docking method.
METHODS: We reviewed 20 patients who underwent total RAMIE with 3FLND by a simultaneous two-team approach at the National Cancer Center East Hospital from March 2023 to September 2023. Short-term surgical outcomes and the safety and efficacy of this technique were analyzed.
RESULTS: The mean operative time for abdominal surgery with this new docking technique was 135 ± 19.6 min. The total operative time was 488 ± 42.9 min, and the time from the end of abdominal manipulation to the end of surgery was 80.1 ± 15.6 min. The intraoperative blood loss was 116.7 ± 64.4 mL. The incidence of anastomotic leakage, postoperative vocal cord paralysis, and postoperative pneumonia was 10%, 5%, and 10%, respectively. The median postoperative hospital stay was 14 days (range 11-63 days). No in-hospital deaths occurred, and R0 resection was possible in all cases. The average number of lymph nodes dissected was 87.7.
CONCLUSION: These results demonstrate that total RAMIE with a simultaneous two-team approach using the new docking method can be safely introduced. The simultaneous cervical and abdominal manipulation with the new docking method allowed total RAMIE without prolonging the operating time, suggesting that it may be a valuable approach for esophageal cancer surgery.
This is a prospective, single site, interventional randomized control trial. The primary purpose is to treat age related health conditions. The current study is nested within an established cohort based in Kashiwa City in Japan, which consists of older adults living independently. The inclusion criteria of this study is age equal to or older than 65 years and functional independence (i.e., not requiring nursing care provided by long-term care insurance). The investigators plan to conduct a randomized controlled trial to test the effectiveness of notification based on Fitbit recorded data, used to prompt health and wellness actions on a variety of health outcomes, compared to usual care. On enrollment, baseline demographic and health information as well as baseline measurements for quality of life, and physical and mental health, will be collected. Subsequently, the study intervention will run for 6 months. Participants in the intervention arm will be given a Fitbit Charge 5 device and asked to wear this for the duration of the study, including during sleep. Participants will receive sessions to teach them how to use the Charge 5 device and access the information produced. Those who meet the above criteria for intervention will receive automatically generated notifications that include lifestyle recommendations. Notifications will be issued using a monitoring software in Japanese, and issued automatically as text alerts to participants. Participants will receive encouraging notifications to promote adherence and health condition. Participants in the control arm will be given a routine care and health-related information. Participants who fail to exhibit a behavior change in the week following the alert, or who are not engaging with the study (e.g., by not wearing the Fitbit device) will be followed up by phone by a member of the community research group. Researchers will compare cognitive performance and physical activity between the two groups to see if the notification based on Fitbit data would promote the health conditions of older adults. Results of this trial will be valuable for informing further implementation of wearable devices and related digital devices in elderly populations in Japan and other countries in the region.
The invention discloses a food mineral supplement capable of effectively treating lupus erythematosus and relates to the fields of foods and medicines. The physiological action is that the low blood calcium condition of the human body can be directly corrected by moderately supplementing the minerals by virtue of three meals a day. The pH value in body fluid is lowered (pH lower than 7.35) due to the long-term low blood calcium, so that Ca<2+> external flow, Na<+>Cl<-> external flow and K<+> internal flow in lymphocyte B in the human body are caused, and therefore, juvenile cells are generated and excessively proliferated to generate excessive antibodies (i.e., specific immunoglobulin), and the excessive antibodies act on the texture cells of the human body to form autoimmune disease. The immune compound, which is difficult to degrade and polymerized into a macromolecule, is infiltrated and deposited in the human tissue, so that micro vessels are blocked to form systemic vasculitis which is the pathological basis of lupus erythematosus and the primary cause of various diseases. Therefore, the food mineral can be supplemented for effectively preventing and treating the lupus erythematosus. The conclusion has been testified in a plurality of clinical practices.